Field Of Vision
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jun 21, 2019; 25(23): 2839-2845
Published online Jun 21, 2019. doi: 10.3748/wjg.v25.i23.2839
Table 1 Comparison of six phase III clinical trials of gemcitabine alone in patients with resected pancreatic cancer
TrialPRODIGE-24[1]CONKO-001[9]ESPAC-3[10]JASPAC 01[13]ESPAC-4[11]CONKO-005[12]

No. of patients246179537190366217
Tumor grade, n (%)
Well differentiated79 (32.1)10 (5.6)66 (12.3)NA30 (8.2)9 (4.1)
Moderately differentiated125 (50.8)103 (57.5)336 (62.6)NA192 (52.5)128 (59)
Poorly differentiated/undifferentiated29 (11.8)63 (35.2)127 (23.6)NA142 (38.8)74 (34.1)
Disease free survival - mo
Overall survival - mo
Table 2 Ongoing clinical trials of replacing part of the FOLFIRINOX regimen with Xeloda/S-1/Nanoliposomal Irinotecan for pancreatic cancer registered in
CountryTitleRegimenPhaseCancer stageEstimated enrollmentStudy completion dateSource
ChinaThe combination chemotherapy of S-1, irinotecan, and oxaliplatin as first line chemotherapy for pancreatic cancerS-1, irinotecan, and oxaliplatinIIUnresectable or metastatic65December 2019NCT03403101
United StatesNeoadjuvant capecitabine, oxaliplatin, and irinotecan chemotherapy in the treatment of pancreatic adenocarcinomaCapecitabine, oxaliplatin, and irinotecanIIResectable, borderline and locally advanced17December 2022NCT01760252
SingaporeOxaliplatin, Xeloda, and irinotecan in pancreatic adenocarcinomaOxaliplatin, Xeloda, and irinotecanIAdvanced and/or metastatic90June 2019NCT02368860
ItalyA study of nanoliposomal irinotecan with 5-fluorouracil, levofolinic acid, and oxaliplatin in patients with resectable pancreatic cancerNanoliposomal irinotecan, oxaliplatin, leucovorin, and 5-fluorouracilIIResectable67January 2020NCT03528785
United StatesStudy of nanoliposomal irinotecan-containing regimens in patients with previously untreated, metastatic pancreatic adenocarcinomaNanoliposomal irinotecan, oxaliplatin, leucovorin, and 5-fluorouracilIIMetastatic56February 2020NCT02551991